{
    "nct_id": "NCT03537599",
    "official_title": "Phase I/II Clinical Trial of Daratumumab and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia Post-Allogeneic Hematopoietic Stem Cell Transplant",
    "inclusion_criteria": "* AML relapse following Allo-HSCT (Morphological relapse, or MRD positive verified by flow cytometry, cytogenetics, and molecular mutations)\n* Relapsed/Refractory AML must not be candidates for available therapies known to be effective for treatment of their AML.\n* MDS transformed to AML following Allo-HCT\n* Patients who received a 10/10 HLA-matched allogeneic HCT either from sibling donors or unrelated donors or atleast a 5/10 haploidentical transplant.\n* Engraftment must have occurred as defined by platelet (PLT) count > 20,000/µL and ANC\n\n  * 0.5\n* Eastern Cooperative Oncology Group (ECOG) performance status < 3\n* Creatinine clearance > 40 ml/min (calculated or measured)\n* Aspartate aminotransferase (AST) < 3 x upper limit of normal (ULN), alanine aminotransferase (ALT) < 3 x ULN\n* Total bilirubin < 1.5 x ULN\n* Off calcineurin inhibitors for at least 2 weeks\n* Prednisone dose ≤ 20 mg/day\n* Patients with proliferative disease can be cytoreduced with cytotoxic chemotherapy at Investigator discretion, but there should be at least a 14 day window between start of cytoreductive therapy and start of daratumumab\n* Blast count ˂20K/day (hydrea use is allowed)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* No demonstrable evidence of donor chimerism (˂ 55% donor CD3 or CD33 chimerism)\n* Patients with a molecular mutation without chromosomal abnormalities or declining chimerisms (MRD status must be verified by surface marker and mutational analyses)\n* Active graft-versus-host disease (GvHD) grades II-IV; prior acute GVHD could have occurred but resolved at time of initiation of daratumumab\n* Extensive chronic GvHD requiring ongoing immunosuppression with calcineurin inhibitors\n* Patients with FLT3+ AML or blast crisis CML who have not yet received post-transplant TKI therapy\n* Active central nervous system (CNS) disease testicular disease\n\nEXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR.; seropositive for hepatitis C (except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy).\n\n* Patients must not have moderate or severe persistent asthma within the past 2 years and must not have currently uncontrolled asthma of any classification.\n* History of grade IV anaphylactic reaction to monoclonal antibody therapy\n* Active autoimmune disease prior to transplant\n* Concurrent use of any other investigational drugs",
    "miscellaneous_criteria": ""
}